. Author manuscript; available in PMC: 2024 Oct 1.

Published in final edited form as: Lancet Child Adolesc Health. 2023 Aug 24;7(10):708–717. doi: 10.1016/S2352-4642(23)00174-8

Table 3:

Multivariable analysis of potential predictors of infant IGRA positivity at 44 weeks (n=732)

	IGRA result^*		Multivariable model
	Positive (n=43)	Negative (n=689)	Adjusted OR (95% CI)	p value
Maternal study group
Immediate isoniazid	21 (49%)	336 (49%)	1·05 (0·55–2·00)	0·88
Deferred isoniazid	22 (51%)	353 (51%)	1 (ref)	..
Maternal TST positive at delivery (or up to 6 weeks postpartum)^†	10 (23%)	87 (1%)	2·09 (0·98–4·44)	0·06
Infant sex
Female	28 (8%)	339 (92%)	2·09 (1·06–4·14)	0·033
Male	15 (4%)	350 (96%)	1 (ref)	..

Data are n (%) or median (IQR), unless stated otherwise. OR indicates likelihood of IGRA positivity. BCG=Bacille Calmette-Guérin. IGRA=interferon-γ release assay. OR=odds ratio. TST=tuberculin skin test.

Positive IGRA was defined as a IFN-γ concentration ≥0·35 IU/mL; negative IGRA included negative and indeterminate results.

^†

Only includes mother–infant pairs for whom data were available.